Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
The following is a summary of the Evogene Ltd. (EVGN) Q1 2024 Earnings Call Transcript:
以下是 Evogene Ltd. (EVGN) Q1 2024 業績會談內容摘要：
Financial Performance:
金融業績：
Evogene reported total revenue of approximately $4.2 million in Q1 2024, a significant increase from $0.6 million in Q1 2023.
Loss reduced to $3.8 million in Q1 2024, showing a decrease of 46% from the $7 million in Q1 2023.
Estimated cash use for 2024 excluding Biomica and Lavie Bio is predicted to be around $8 million, a 36% decrease year-over-year.
The closure of Canonic's operation was finalized, resulting in an annualized saving of $1.5 million.
Evogene 報告 Q1 2024 營業收入約爲 420 萬美元，較 Q1 2023 的 60 萬美元顯著增長。
Q1 2024 虧損減少至 380 萬美元，較 Q1 2023 的 700 萬美元減少了 46%。
預計 2024 年除了 Biomica 和 Lavie Bio 外的現金支出預測約爲 800 萬美元，同比減少 36%。
Canonic 的操作關閉已經敲定，每年可節省 1.5 百萬美元。
Business Progress:
業務進展：
Partnerships with Verb Biotics and The Kitchen FoodTech Hub have been established and Finally Foods has been set up.
Casterra secured agreements with African and Brazilian seed growers to fulfill standing orders by the end of 2024.
Launch of Phase I clinical trial results for Biomica's BMC128 microbiome therapeutics at the 2024 ASCO Conference is in pipeline.
Lavie Bio initiated a new collaboration with Syngenta and received $2.5 million from Corteva.
AgPlenus announced a new collaboration with Bayer as operations of Canonic ceased due to challenging market conditions in the medical cannabis sector.
Evogene is planning to build an inventory for 2025, resourced initially by Evogene and later by partners' revenues.
The company conveys confidence in the uniqueness and versatility of their Computational Biology Platform (CBP) technology, aiming to enhance it through increasing number of partnerships.
已經與 Verb Biotics 和 The Kitchen FoodTech Hub 建立了合作伙伴關係，成立了 Finally Foods。
Casterra 已經與非洲和巴西種子種植者達成協議，以滿足截至 2024 年底的備貨訂單。
Biomica 的 BMC128 微生物組治療項⽬的 I 期臨床試驗結果將在 2024 年 ASCO (美國臨床腫瘤學會) 大會上公佈。
Lavie Bio 與 Syngenta 開始了新的合作，並從 Corteva 獲得了 250 萬美元。
由於醫療大麻板塊市場條件不佳，Canonic 的運營已經停止，AgPlenus 宣佈與拜耳新成立了合作關係。
Evogene 計劃建立 2025 年的庫存，最初由 Evogene 提供資金，後續由合作伙伴的營收支持。
公司對其計算生物學平台 (CBP) 技術的獨特性和多樣性充滿信心，旨在通過增加合作伙伴的數量來增強其功能。
More details: Evogene IR
更多詳情：Evogene 投資者關係 (IR)
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。